rethinkPeptides Search
Menu
Research citation

GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.

Narrative ReviewModerate evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

What the researchers found

GLP-1 RAs increase gallstone and gallbladder inflammation risk through suppression of cholecystokinin, altered bile acid composition, and rapid weight loss-related cholesterol supersaturation.

Why it matters

Gallbladder problems are one of the most clinically significant side effects of GLP-1 drugs. Understanding the mechanisms could help prevent them.

The numbers in context

Mechanisms: CCK suppression, bile acid alterations, weight loss-related cholesterol supersaturation; risk increases with dose and duration.

How the study worked

Narrative review of molecular mechanisms and clinical evidence for GLP-1 RA-associated biliary disease.

Who was studied

Patients on GLP-1 RAs for T2DM or obesity

What this study cannot tell us

Narrative format. Absolute risk increase is modest. Difficult to separate drug effect from rapid weight loss effect. Prevention strategies not well established.

Read the original research

GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.

Therapeutic advances in endocrinology and metabolism, 16, 20420188251406456

Citation

Ramírez-Mejía, Mariana M; Ponciano-Rodriguez, Guadalupe; Eslam, Mohammed; Méndez-Sánchez, Nahum. (2025). GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.. Therapeutic advances in endocrinology and metabolism, 16, 20420188251406456. https://doi.org/10.1177/20420188251406456